BioCryst Pharmaceuticals

BCRX

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug RAPIVAB was approved by FDA in Dec 2014.

BioCryst Pharmaceuticals has been a target of short sellers for a while. The current short interest of 13.33% is roughly at the average of the last 12 months (14.37%).